Additional File of Elevated Expression of LPCAT1 Predicts a Poor Prognosis and is Correlated with the Tumour Microenvironment in Endometrial Cancer

Tianyi Zhao,Min Han,Xiaohong Ma,Lina Wei,Yixin Hou,Rui Sun,Jie Jiang

DOI: https://doi.org/10.6084/m9.figshare.14633817.v1

2021-01-01

Abstract:Additional file of Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer

What problem does this paper attempt to address?

Additional File 3 of Elevated Expression of LPCAT1 Predicts a Poor Prognosis and is Correlated with the Tumour Microenvironment in Endometrial Cancer

Tianyi Zhao,Min Han,Xiaohong Ma,Lina Wei,Yixin Hou,Rui Sun,Jie Jiang

DOI: https://doi.org/10.6084/m9.figshare.14633808

2021-01-01

Abstract:Additional file 3: Table S1. Immune scores and stromal scores of EC.
Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer

Tianyi Zhao,Yifang Zhang,Xiaohong Ma,Lina Wei,Yixin Hou,Rui Sun,Jie Jiang

DOI: https://doi.org/10.1186/s12935-021-01965-1

IF: 6.429

2021-05-20

Cancer Cell International

Abstract:Abstract Background Endometrial cancer (EC) is one of the three malignant reproductive tumours that threaten women’s lives and health. Glycerophospholipids (GPLs) are important bioactive lipids involved in various physiological and pathological processes, including cancer. Immune infiltration of the tumour microenvironment (TME) is positively associated with the overall survival in EC. Exploring GPL-related factors associated with the TME in endometrial cancer can aid in the prognosis of patients and provide new therapeutic targets. Methods Differentially expressed GPL-related genes were identified from TCGA-UCEC datasets and the Molecular Signatures Database (MSigDB). Univariate Cox regression analysis was used to select GPL-related genes with prognostic value. The Random forest algorithm, LASSO algorithm and PPI network were used to identify critical genes. ESTIMATEScore was calculated to identify genes associated with the TME. Then, differentiation analysis and survival analysis of LPCAT1 were performed based on TCGA datasets. GSE17025 and immunohistochemistry (IHC) verified the results of the differentiation analysis. An MTT assay was then conducted to determine the proliferation of EC cells. GO and KEGG enrichment analyses were performed to explore the underlying mechanism of LPCAT1. In addition, we used the ssGSEA algorithm to explore the correlation between LPCAT1 and cancer immune infiltrates. Results Twenty-three differentially expressed GPL-related genes were identified, and eleven prognostic genes were selected by univariate Cox regression analysis. Four significant genes were identified by two different algorithms and the PPI network. Only LPCAT1 was significantly correlated with the tumour microenvironment. Then, we found that LPCAT1 was highly expressed in tumour samples compared with that in normal tissues, and lower survival rates were observed in the groups with high LPCAT1 expression. Silencing of LPCAT1 inhibited the proliferation of EC cells. Moreover, the expression of LPCAT1 was positively correlated with the histologic grades and types. The ROC curve indicated that LPCAT1 had good prognostic accuracy. Receptor ligand activity, pattern specification process, regionalization, anterior/posterior pattern specification and salivary secretion pathways were enriched as potential targets of LPCAT1. By using the ssGSEA algorithm, fifteen kinds of tumor-infiltrating cells (TICs) were found to be correlated with LPCAT1 expression. Conclusion These findings suggested that LPCAT1 may act as a valuable prognostic biomarker and be correlated with immune infiltrates in endometrial cancer, which may provide novel therapy options for and improved treatment of EC.

oncology
Identification of a 3-Cuproptosis-associated-lncrna-signature That Predicts the Prognosis of Endometrial Cancer Patients

Tianyi Liu,Xinyu Wang,Manyu Li,Tianyu Zhu,Cheng Qiu,Chuhan He,Lanyu Li,Jinfeng Qu

DOI: https://doi.org/10.22514/ejgo.2023.073

2024-01-01

European Journal of Gynaecological Oncology

Abstract:Endometrial carcinoma is a common malignancy among peri-menopausal and menopausal females, even among some women of reproductive age. The treatment approach to endometrial cancer is a platinum-based regimen combined with paclitaxel, which may be unsatisfactory. A copper-mediated binding of lipoylated constituents of tricarboxylic acid cycle has been found recently, which brings about lethal protein stress and cell death, a phenomenon termed cuproptosis. As an innovative method of cell death, cuproptosis could be designed for cancer treatment and many aspects remain unaddressed. In our study, clinical, genomic, and mutational profiles of uterine corpus endometrial carcinoma (UCEC) patients were obtained from The Cancer Genome Atlas and cuproptosis-related genes and long non-coding RNAs (lncRNAs) were acquired thereafter. Co-expression and Cox regression analyses led to the development of a prognostic signature. Patients were separated into two groups (high- and low-risk groups) and survival analysis, risk score calculation, multivariate Cox analysis, and subgroup validation were implemented to determine the utility of the signature. Differentially expressed genes (DEGs) between the two groups were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Immune-related functional analysis and tumor mutation burden (TMB) analysis were performed. Three independent high-risk cuproptosis-related lncRNAs were finally confirmed and incorporated into the prognostic model, including BX322234.1, LINC01545 and LINC01224. Areas under the curve for 1-, 3- and 5-year survival were 0.717, 0.688 and 0.714, respectively. The risk model served as an independent factor to predict prognosis. Patients with high-risk and low TMB tended to have poor prognoses. Enrichment analysis demonstrated that DEGs were mostly associated with immune responses. In conclusion, the three high-risk cuproptosis-related lncRNAs could predict the prognosis of UCEC patients with higher power, where patients with high-risk and low TMB are prone to have the worst prognosis, which broadens the pattern of clinical treatment and applications.
LPCAT1 is a Prognostic Biomarker and Correlated with Tumor Microenvironment in Endometrial Cancer

Tianyi Zhao,Yifang Zhang,Xiaohong Ma,Lina Wei,Yixin Hou,Rui Sun,Jie Jiang

DOI: https://doi.org/10.21203/rs.3.rs-304931/v1

2021-01-01

Abstract:Abstract Background: Endometrial cancer (EC) is one of the three malignant reproductive tumors threatening women’s life and health. Glycerophospholipids (GPLs) are important bioactive lipids involved in various physiological and pathological processes including cancer. Immune-infiltration of the tumor microenvironment (TME) is positively associated with the overall survival in EC. Exploring GPLs-related factors associated with TME in endometrial cancer can aid in the prognosis of patients and provide new therapy targets. Methods: Differentially expressed GPLs-related genes were identified from TCGA-UCEC datasets and Molecular Signatures Database (MSigDB). Univariate Cox regression analysis was used to select GPLs-related genes with prognostic values. Random forest algorithm, LASSO algorithm and PPI network were used to identify critical genes. ESTIMATEScore was calculated to find out genes associated with TME. Then, differentiation analysis and survival analysis of LPCAT1 were performed based on TCGA datasets. GSE17025 and immunohistochemistry (IHC) verified the results of differentiation analysis. GO and KEGG enrichment analyses were performed to explore the underlying mechanism. In addition, we used ssGSEA algorithm to explore the correlation between LPCAT1 and cancer immune infiltrates.Results: Twenty-three differentially expressed GPLs-related genes were identified and eleven prognostic genes were selected by Univariate Cox regression analysis. Four significant genes were found out by two different algorithms and PPI network. Only LPCAT1 was significantly correlated with tumor microenvironment. Then, we found that LPCAT1 was highly expressed in tumors samples compared with normal tissues, and lower survival rates was along with high expression groups of LPCAT1. Moreover, the expression of LPCAT1 was positively correlated with histologic grades and types. ROC curve indicated LPCAT1 had good accuracy of prognostic value. Receptor ligand activity, pattern specification process, regionalization, anterior/posterior pattern specification and salivary secretion pathways were enriched as potential targets of LPCAT1. By using ssGSEA algorithm, fifteen kinds of tumor infiltrating cells (TICs) were found correlated with LPCAT1 expression.Conclusion: These findings suggested that LPCAT1 was a valuable prognostic biomarker and correlated with immune infiltrates in endometrial cancer, which may provide novel therapy options and improved treatment of EC.
Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

Luya Cai,Limeng Cai,Lin Zhou,Yating Zhao,Jianhua Qian

DOI: https://doi.org/10.1177/03000605231213435

2023-01-01

Journal of International Medical Research

Abstract:ObjectiveEndometrial cancer (EC) is one of the most prevalent cancers in women. Long non-coding RNAs (lncRNAs) are potential diagnostic biomarkers in patients with EC.MethodsWe obtained clinical information and transcriptome data for 552 patients with EC from The Cancer Genome Atlas database. Cuproptosis-associated lncRNAs were obtained through Pearson's correlation analysis. Univariate and multivariate Cox regression analyses were applied and a signature predicting overall survival (OS) among patients with EC was constructed. We also analyzed the tumor immune microenvironment and drug sensitivity. The results were validated by quantitative real time-polymerase chain reaction, and 5-ethynyl-2 '-deoxyuridine and wound-healing assays.ResultsSeven cuproptosis-associated lncRNAs related to prognosis were screened out and a signature was constructed. OS was significantly superior in the low-risk group. In addition, patients in the low-risk group had more CD8+ T cell infiltration, a stronger type II interferon response, and greater cisplatin sensitivity. Expression levels of some of the lncRNAs were significantly increased by cuproptosis. Furthermore, silencing of lncRNA AC084117.1 significantly inhibited the proliferation and migration of EC cells.ConclusionWe constructed a seven cuproptosis-associated lncRNA signature to predict the prognosis of patients with EC with good predictive power.
LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma

Huafeng Pan,Wei Wei,Guanghou Fu,Jiaren Pan,Baiye Jin

DOI: https://doi.org/10.3390/medicina59020187

2023-01-01

Abstract:Background and Objectives: A significant role was played by costimulatory molecules in renal cancer. However, the lncRNAs regulating costimulatory molecules have not been fully investigated. Materials and Methods: Data from the next-sequence file and clinical data were downloaded from the Cancer Genome Atlas (TCGA) database. All analyses were conducted using the R and GraphPad Prism software. Results: A total of 1736 costimulatory molecule-related lncRNAs were determined under the threshold of |Cor| > 0.5 and p-value < 0.001. Furthermore, a prognosis prediction signature consisting of five lncRNAs: LINC00941, AC016773.1, AL162171.1, HOTAIRM1, and AL109741.1 was established with great prediction ability. By combining risk score and clinical parameters, a nomogram plot was constructed for better clinical practice. A biological enrichment analysis indicated that E2F targets, coagulation, IL6/JAK/STAT3 signaling, G2/M checkpoint, and allograft rejection pathways were activated in high-risk patients. Furthermore, a higher infiltration level of resting CD4+ T cell, M2 macrophage, and resting mast cells, while a lower CD8+ T cell infiltration was observed in high-risk patients. It is worthy of note that, low-risk patients might respond better to PD-1 checkpoint therapy. A correlation analysis of LINC00941 revealed that it was positively correlated with Th2 cells, Th1 cells, macrophages, and Treg cells, but negatively correlated with Th17 cells. A pathway enrichment analysis indicated that the pathways of the inflammatory response, G2M checkpoint, and IL6/JAK/STAT3 signaling were significantly activated in patients with high LINC00941 expression. In vitro experiments indicated that LINC00941 can enhance the malignant biological behaviors of renal cancer cells. Conclusions: Our study established a costimulatory molecule-related lncRNAs-based prognosis model with a great prediction prognosis. In addition, LINC00941 could enhance the malignant biological behaviors of renal cancer cells.
Overexpression of LPCAT1 Enhances Endometrial Cancer Stemness and Metastasis by Changing Lipid Components and Activating TGF-β/Smad2/3 Signaling Pathway

Tianyi Zhao,Rui Sun,Xiaohong Ma,Lina Wei,Yixin Hou,Kun Song,Jie Jiang

DOI: https://doi.org/10.3724/abbs.2022076

IF: 3.7

2022-01-01

Acta Biochimica et Biophysica Sinica

Abstract:The incidence of endometrial cancer(EC)increases annually and tends to occur in younger women.A particularly important relationship exists between EC and metabolic disorders.As one of the most important components of lipid metabolism,phospholipids play an indispensable role in metabolic balance.LPCAT1 is a key enzyme regulating phospholipid metabolism.In this study,we perform further investigations to seek mechanistic insight of LPCAT1 in EC.Our results demonstrate that silencing of LPCAT1 inhibits the growth of endometrial cancer,while over-expression of LPCAT1 results in enhanced stemness and metastasis in endometrial cancer cell lines.Meanwhile,the contents of various phospholipids including phosphatidylethanolamine(PE),phosphatidylcholine(PC),and trigly-ceride(TG)change significantly after overexpression of LPCAT1.In addition,through RNA-sequencing and western blot analysis,we observe that the TGF-β/Smad2/3 signaling pathway is of great importance in the tumor-promoting function of LPCAT1.LPCAT1 promotes the expressions of stem cell-related transcription factors and epithelial-mesenchymal transition(EMT)related proteins through the TGF-β/Smad2/3 signaling pathway.Moreover,we find that TSI-01,which can inhibit the activity of LPCAT1,is able to restrain the proliferation of EC cell lines and promote cell apoptosis.Collectively,we demonstrate that LPCAT1 enhances the stemness and metastasis of EC by activating the TGF-β/Smad2/3 signaling pathway and that TSI-01 may have potential use for the treatment of EC.
Additional File 1 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

Weiwei Feng,Jun Nan,Haining Jiao,Jun Chen,Chen‐Hua Yan,Yueru Zhang,Menghan Zhu,Chongying Zhu,Lifei Shen,Wuqiang Long

DOI: https://doi.org/10.6084/m9.figshare.13710992

2021-01-01

Abstract:Additional file 1: Table S1. Clinicopathological characteristic of detected cases.
Laptm4b-35 Overexpression Is An Independent Prognostic Marker In Endometrial Carcinoma

Fan-ling Meng,Ming-zhu Yin,Hong-tao Song,Hua Yang,Ge Lou,Rou-li Zhou

DOI: https://doi.org/10.1111/IGC.0b013e3181e02f90

2010-01-01

International Journal of Gynecological Cancer

Abstract:Background: Lysosomal protein transmembrane 4 beta-35 (LAPTM4B-35), a novel oncoprotein that belongs to the mammalian 4-tetratransmembrane spanning protein superfamily, has been implicated in oncogenesis and cancer progression in several solid malignances. However, the expression of LAPTM4B-35 and its role in endometrial cancer progression remain unknown.Materials and Methods: We investigated the expression of the LAPTM4B-35 protein by immunohistochemistry in 30 normal endometrium specimens and 165 endometrial carcinomas and analyzed its correlation with various clinicopathologic features, including patient outcome.Results: LAPTM4B-35 immunoreactivity was overexpressed in endometrial carcinoma cases compared with normal endometrium (P < 0.001). High LAPTM4B-35 expression was found in 117 (70.91%) of these 165 carcinomas and was positively correlated with the International Federation of Gynecology and Obstetrics stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence, but not with age and histological type. Patients with high LAPTM4B-35 expression had significantly poorer overall survival and disease-free survival compared with patients with low expression of LAPTM4B-35 (P = 0.001 and P = 0.002, respectively). Multivariate analysis showed that high LAPTM4B-35 expression was an independent prognostic factor for both overall survival and disease-free survival of patients with endometrial carcinoma (both P = 0.005).Conclusions: These results showed that high LAPTM4B-35 expression was associated with progression and prognosis of endometrial carcinoma.
Additional File 3 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

Weiwei Feng,Jun Nan,Haining Jiao,Jun Chen,Chen‐Hua Yan,Yueru Zhang,Menghan Zhu,Chongying Zhu,Lifei Shen,Wuqiang Long

DOI: https://doi.org/10.6084/m9.figshare.13710998

2021-01-01

Abstract:Additional file 3: Table S3. Pathogenic/Likely pathogenic mutations* in detected cases.
High L1CAM expression predicts poor prognosis of patients with endometrial cancer A systematic review and meta-analysis

Min Guo,Han Gong,Dan Nie,Zhengyu Li

DOI: https://doi.org/10.1097/MD.0000000000025330

IF: 1.6

2021-01-01

Medicine

Abstract:Backgroud: Previous studies have reported that the levels of L1 cell adhesion molecule (L1CAM) indicate poor prognosis of patients with various solid tumors. However, the prognostic significance of L1CAM in endometrial cancer has remained controversial. Herein, we conducted a systematic review and meta-analysis to evaluate the prognostic value of L1CAM in endometrial cancer. Methods: All studies related to the association between L1CAM expression and clinical characteristics of endometrial cancer were identified by searching the PubMed, MEDLINE, EMBASE, and Web of Science databases. Primary outcomes of the meta-analysis were the hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS). Secondary outcomes were odds ratios (ORs) for clinicopathological characteristics. Publication bias and sensitivity analysis were conducted to ensure reliability of the results. Results: Overall, 17 studies encompassing 7146 patients were eligible for the meta-analysis. Results showed L1CAM overexpression to be significantly associated with decreased overall survival (HR = 2.87, 95% CI; 1.81-4.55, P < .001) and disease-free survival (HR = 3.32, 95% CI; 1.99-5.55, P < .001) in patients with endometrial cancer. High L1CAM expression was also related to adverse clinicopathological characteristics. Conclusion: This systematic review demonstrated that high L1CAM expression is correlated with poor survival outcomes and adverse clinicopathological parameters in patients with endometrial cancer.
Additional File 1 of Tumor-derived KLK8 Predicts Inferior Survival and Promotes an Immune-Suppressive Tumor Microenvironment in Lung Squamous Cell Carcinoma

He Tian,Ran Wei,Xiao Chu,Tao Fan,Yun Cao,Tiejun Liu,Bo Zheng,Chunxiang Li,Jie He

DOI: https://doi.org/10.6084/m9.figshare.25067217

2024-01-01

Abstract:Additional file 1: Supplementary Data 1. Immune infiltration within the tumor microenvironment for low-KLK8 and high-KLK8 patient groups.
Identification of Molecular Markers Associated with the Progression and Prognosis of Endometrial Cancer: a Bioinformatic Study

JinHui Liu,Mingming Feng,SiYue Li,Sipei Nie,Hui Wang,Shan Wu,Jiangnan Qiu,Jie Zhang,WenJun Cheng

DOI: https://doi.org/10.1186/s12935-020-1140-3

IF: 6.429

2020-01-01

Cancer Cell International

Abstract:Background Endometrial cancer (EC) is one kind of women cancers. Bioinformatic technology could screen out relative genes which made targeted therapy becoming conventionalized. Methods GSE17025 were downloaded from GEO. The genomic data and clinical data were obtained from TCGA. R software and bioconductor packages were used to identify the DEGs. Clusterprofiler was used for functional analysis. STRING was used to assess PPI information and plug-in MCODE to screen hub modules in Cytoscape. The selected genes were coped with functional analysis. CMap could find EC-related drugs that might have potential effect. Univariate and multivariate Cox proportional hazards regression analyses were performed to predict the risk of each patient. Kaplan-Meier curve analysis could compare the survival time. ROC curve analysis was performed to predict value of the genes. Mutation and survival analysis in TCGA database and UALCAN validation were completed. Immunohistochemistry staining from Human Protein Atlas database. GSEA, ROC curve analysis, Oncomine and qRT-PCR were also performed. Results Functional analysis showed that the upregulated DEGs were strikingly enriched in chemokine activity, and the down-regulated DEGs in glycosaminoglycan binding. PPI network suggested that NCAPG was the most relevant protein. CMap identified 10 small molecules as possible drugs to treat EC. Cox analysis showed that BCHE, MAL and ASPM were correlated with EC prognosis. TCGA dataset analysis showed significantly mutated BHCE positively related to EC prognosis. MAL and ASPM were further validated in UALCAN. All the results demonstrated that the two genes might promote EC progression. The profile of ASPM was confirmed by the results from immunohistochemistry. ROC curve demonstrated that the mRNA levels of two genes exhibited difference between normal and tumor tissues, indicating their diagnostic efficiency. qRT-PCR results supported the above results. Oncomine results showed that DNA copy number variation of MAL was significantly higher in different EC subtypes than in healthy tissues. GSEA suggested that the two genes played crucial roles in cell cycle. Conclusion BCHE, MAL and ASPM are tumor-related genes and can be used as potential biomarkers in EC treatment.
LPCAT1 Acts As an Independent Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma

Lan Li,Xiao Wang,Yanni Ding,Nini Hui,Bingjie Su,Min Yang

DOI: https://doi.org/10.1186/s40001-022-00854-1

IF: 4.981

2022-01-01

European Journal of Medical Research

Abstract:Background Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is overexpressed in multiple human tumors. However, the role of LPCAT1 in hepatocellular carcinoma (HCC) has not been understood. We aim to explore the relationships between LPCAT1 expression and prognosis, clinicopathological features, tumor microenvironment (TME), immune cell infiltration, immune checkpoint gene expression, and related signaling pathways in HCC. Furthermore, we also explored the relationship between LPCAT1 expression and drug sensitivity to HCC treatment. Methods The expression profiles were acquired from the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (THPA). Immune status and infiltration in cancer tissues were explored using the single sample gene set enrichment analysis (ssGSEA) and CIBERSORT algorithm. Results LPCAT1 was overexpressed in HCC, and its expression was related to poor prognosis, LPCAT1 was an independent prognostic biomarker in HCC. Expression of LPCAT1 increased statistically with the increase of clinical stage and grade of HCC patients. GO and KEGG network analysis revealed that LPCAT1 positively associated molecules were mostly enriched in functions related to cell adhesion. The TME score of high-LPCAT1 group was significantly higher than that of low-LPCAT1 group. Immune infiltrating cells positively correlated with LPCAT1 expression were Macrophages M0, B cells memory, Dendritic cells activated, T cells regulatory and T cells gamma delta in HCC. We found a positive correlation between LPCAT1 and most immune checkpoint gene expression. The IC50 of 5-Fluorouracil, Gemcitabine, Mitomycin C, Sorafenib and Cabozantinib in patients with high-LPCAT1 expression was lower than that in patients with low-LPCAT1 expression. Our findings provide a wealth of information for further understanding of the biological functions and signaling pathways of LPCAT1 in HCC. Conclusions LPCAT1 is an independent prognostic biomarker and associated with tumor microenvironment, immune cell infiltration, immune checkpoint expression and drug sensitivity in hepatocellular carcinoma.
Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer: A field synopsis of observational study

Wenxue Li,Yujing Qin,Xiujuan Chen,Xiaolei Wang

DOI: https://doi.org/10.1097/MD.0000000000034047

2023-06-23

Abstract:Endometrial cancer (EC) is the sixth most common malignant tumor in women worldwide, and its morbidity and mortality are on the rise. The purpose of this study was to explore potential tumor microenvironment (TME)-related biomarkers associated with the clinical features and prognosis of EC. The Estimating Stromal and Immune Cells in Malignancy Using Expression Data (ESTIMATE) algorithm was used to calculate TME immune and stromal scores of EC samples and to analyze the relationship between immune/stromal scores, clinical features, and prognosis. Heat maps and Venn maps were used to screen for differentially expressed genes (DEGs). The ESTIMATE algorithm revealed immune score was significantly correlated with overall survival and tumor grade in patients with EC. A total of 1448 DEGs were screened, of which 387 were intersecting genes. Gene Ontology (GO) analysis revealed that the biological processes (BP) related to intersecting genes mainly included T cell activation and regulation of lymphocyte activation. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that the intersecting genes were closely related to immune-related signaling pathways. Thirty core genes with more than 7 nodes were identified using protein-protein interaction (PPI) analysis. Six independent prognostic genes of EC were identified using Kaplan-Meier survival analysis and multivariate Cox analysis, namely CD5, BATF, CACNA2D2, LTA, CD52, and NOL4, which are all immune-infiltrating genes that are closely related to clinical features. The current study identified 6 key genes closely related to immune infiltration in the TME of EC that predict clinical outcomes, which may provide new insights into novel prognostic biomarkers and immunotherapy for patients with EC.
Integrative Analysis of Differently Expressed Genes Reveals a 17-Gene Prognosis Signature for Endometrial Carcinoma.

Anna Wang,Hongyan Guo,Zaiqiu Long

DOI: https://doi.org/10.1155/2021/4804694

2021-01-01

BioMed Research International

Abstract:Endometrial carcinoma (EC) is the fifth widely occurring malignant neoplasm among women all over the world. However, there is still lacking efficacy indicators for EC's prognosis. Here, we analyzed two databases including an RNA-sequencing-based TCGA dataset and a microarray-based GSE106191. After normalizing the raw data, we identified 114 common genes with upregulation and 308 common genes with downregulation in both the TCGA and GSE106191 databases. Bioinformatics analysis showed that the differently expressed genes in EC were related to the IL17 signaling pathway, PI3K-Akt signaling pathway, and cGMP-PKG signaling pathway. Furthermore, we performed the least absolute shrinkage and selection operator (LASSO) Cox regression analysis and generated a signature featuring 17 prognosis-related genes (MAL2, ANKRD22, METTL7B, IL32, ERFE, OAS1, TRPC1, SRPX, RAPGEF4, PSD3, SIMC1, TRPC6, WFS1, PGR, PAMR1, KCNK6, and FAM189A2) and found that it could predict OS in EC patients. The further analysis showed that OAS1, MAL2, ANKRD22, METTL7B, and IL32 were significantly upregulated in EC samples after comparison with normal samples. However, TRPC1, SRPX, RAPGEF4, PSD3, SIMC1, TRPC6, WFS1, PGR, PAMR1, KCNK6, and FAM189A2 were significantly downregulated in EC samples in comparison with normal samples. And correlation analysis showed that our results showed that the expressions of 17 prognosis-related hub genes were significantly correlated based on Pearson correlation. We here offer a newly genetic biomarker for the prediction of EC patients' prognosis.
LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

Hongbin Zhang,Ke Xu,Qin Xiang,Lijuan Zhao,Benxu Tan,Ping Ju,Xiufu Lan,Yi Liu,Jian Zhang,Zheng Fu,Chao Li,Jinzhi Wang,Jixiang Song,Yun Xiao,Zhaobo Cheng,Yan Wang,Shu Zhang,Tingxiu Xiang

DOI: https://doi.org/10.1016/j.gendis.2020.07.007

2022-01-01

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>This study aimed to investigate the relationships between LPCAT1 expression and clinicopathologic parameters of hepatocellular carcinoma (HCC), further, to explore the effect of LPCAT1 on overall survival (OS) in patients with HCC, and its possible mechanism.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Bioinformatics analysis using high throughput RNA-sequencing data from TCGA was utilized to explore the differential expression of LPCAT1 between normal and tumor tissues, and the associations between LPCAT1 expression and clinicopathological parameters. Survival analyses and subgroup survival analyses were utilized to elucidate the effect of LPCAT1 on OS in patients with HCC. Univariate analysis and multivariate analysis were used to investigate the prognostic factors. Potential LPCAT1 related tumor genes were identified by the methodology of differentially expressed genes (DEGs) screening. GO term enrichment analysis, KEGG pathway analysis and the PPI network were used to explore the potential mechanism.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>LPCAT1 was significantly overexpressed in HCC tumor tissues compared with normal tissues. The LPCAT1 expression was related to tumor grade, ECOG score, AFP and TNM stage, with <em>p</em> values of 0.000, 0.000, 0.007 and 0.000, respectively. Multivariate analysis demonstrated that LPCAT1 expression was independently associated with OS, with an HR of 1.04 (CI: 1.01–1.06, <em>p</em> = 0.004). The KEGG pathway enrichment analyses showed that overlapped DEGs mainly participate in the cell cycle. Finally, we identified a hub gene, CDK1, which has been reported to act on the cell cycle, consistent with the result of KEGG enrichment analysis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>LPCAT1 was upregulated in HCC, and was an independent predictor of the prognosis.</p>

genetics & heredity,biochemistry & molecular biology
Exploration of a Novel Prognostic Risk Signatures and Immune Checkpoint Molecules in Endometrial Carcinoma Microenvironment

Jinhui Liu,Sipei Nie,Zhipeng Wu,Yi Jiang,Yicong Wan,Siyue Li,Huangyang Meng,Shulin Zhou,Wenjun Cheng

DOI: https://doi.org/10.2139/ssrn.3566118

2020-01-01

SSRN Electronic Journal

Abstract:The effectiveness of immunotherapy in treating endometrial carcinoma (EC) remains to be testified. In this study, we explored the underlying mechanism through tumor microenvironment (TME) and immune-related genes in EC. Based on The Cancer Genome Atlas (TCGA) database, we found 799 up-regulated and 139 down-regulated immune-related and differentially expressed genes of EC. Then, prognostic genes were screened out, functional annotations and interpreted interaction network of these genes were further investigated for the underlying regulation mechanisms. Moreover, by a conjoint Cox regression analysis, we built two risk models based on key prognostic immune-related genes, which identified respectively for overall survival and disease-free survival. Gene set enrichment analysis revealed immune-related pathways were mostly enriched in gene sets of the low-risk group, and the nomograms were constructed based on the risk models. We further explored the predictive value of risk signatures by exploring the tumor-infiltrating immune cells, prognostic immune checkpoints modulators, and checkpoint inhibitors in TME. We found higher immune cell infiltration and activation in low risk tumor tissues, which might cause lower tumor purity and contribute to better prognosis. Both the expression and immunophenoscore of immune checkpoints PD-1, CTLA4, PD-L1 and PD-L2 increased significantly in low-risk group. In addition, the low-risk group were found display higher tumor mutational burden. In summary, our study proved that high-immune TME might prevent the progression of EC, which indicated the possibility of immunotherapy to fight against EC.Funding Statement: National Natural Science Foundation (81472442, 81872119) and Jiangsu province medical innovation team (CXTDA2017008) supported our study.Declaration of Interests: The authors have no conflicts of interest to declare.
Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer

Peigen Chen,Yuebo Yang,Yu Zhang,Senwei Jiang,Xiaomao Li,Jing Wan

DOI: https://doi.org/10.18632/aging.102817

2020-02-19

Abstract:Endometrial cancer (EC) is one of the most common gynecologic malignancies. To identify potential prognostic biomarkers for EC, we analyzed the relationship between the EC tumor microenvironment and gene expression profiles. Using the ESTIMATE R tool, we found that immune and stromal scores correlated with clinical data and the prognosis of EC patients. Based on the immune and stromal scores, 387 intersection differentially expressed genes were identified. Eight immune-related genes were then identified using two machine learning algorithms. Functional enrichment analysis revealed that these genes were mainly associated with T cell activation and response. Kaplan-Meier survival analysis showed that expression of TMEM150B, CACNA2D2, TRPM5, NOL4, CTSW, and SIGLEC1 significantly correlated with overall survival times of EC patients. In addition, using the TIMER algorithm, we found that expression of TMEM150B, SIGLEC1, and CTSW correlated positively with the tumor infiltration levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, and dendritic cells. These findings indicate that the composition of the tumor microenvironment affects the clinical outcomes of EC patients, and suggests that it may provide a basis for development of novel prognostic biomarkers and immunotherapies for EC patients.
TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma

Ke Shi,Xiao-Li Liu,Qiang Guo,Yun-Qiang Zhang,Si-Tong Fan,Ling Dai,Ni Jiang,Dan Li

DOI: https://doi.org/10.1371/journal.pone.0285817

IF: 3.7

2023-07-21

PLoS ONE

Abstract:Background Expression levels of transmembrane protein 41A ( TMEM41A) are related to the progression of malignant tumors. However, the association between TMEM41A expression and endometrial carcinoma (EC) remains unclear. This study aims to identify the roles of TMEM41A expression in the prognosis of patients with EC and its correlation with EC progression. Methods The TMEM41A expression and its correlation with the survival of patients with EC were assessed. Cox regression analysis was used to identify the prognostic factors, while nomograms were used to examine the association between the prognostic factors and the survival of patients with EC. Finally, the link between TMEM41A level and immune microenvironment and RNA modifications was investigated in EC. Results TMEM41A was overexpressed in EC. TMEM41A overexpression could diagnose the EC and evaluate the poor prognosis of patients. Overexpression of TMEM41A was associated with clinical stage, age, weight, histological subtype, tumor grade, and survival status of patients with EC. Clinical stage, age, tumor grade, radiotherapy, and TMEM41A overexpression were factors of poor prognosis in patients with EC. The nomograms revealed the correlation between the TMEM41A level and survival time of patients with EC at 1, 3, and 5 years. Furthermore, TMEM41A overexpression was significantly correlated with the level of the stromal score, immune score, estimate score, NK CD56 bright cells, iDC, NK cells, eosinophils, pDC, T cells, TReg, cytotoxic cells, mast cells, Th17 cells, neutrophils, aDC, NK CD56 dim cells, TFH, Th2 cells, CD8 T cells, macrophages, immune cell markers, and RNA modifications. Conclusions TMEM41A is overexpressed in EC tissues and is associated with the prognosis, immune microenvironment, and RNA modification. Our preliminary studies indicate that overexpression of TMEM41A can potentially serve as a biomarker for EC treatment.

multidisciplinary sciences

Additional File of Elevated Expression of LPCAT1 Predicts a Poor Prognosis and is Correlated with the Tumour Microenvironment in Endometrial Cancer

Additional File 3 of Elevated Expression of LPCAT1 Predicts a Poor Prognosis and is Correlated with the Tumour Microenvironment in Endometrial Cancer

Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer

Identification of a 3-Cuproptosis-associated-lncrna-signature That Predicts the Prognosis of Endometrial Cancer Patients

LPCAT1 is a Prognostic Biomarker and Correlated with Tumor Microenvironment in Endometrial Cancer

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma

Overexpression of LPCAT1 Enhances Endometrial Cancer Stemness and Metastasis by Changing Lipid Components and Activating TGF-β/Smad2/3 Signaling Pathway

Additional File 1 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

Laptm4b-35 Overexpression Is An Independent Prognostic Marker In Endometrial Carcinoma

Additional File 3 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

High L1CAM expression predicts poor prognosis of patients with endometrial cancer A systematic review and meta-analysis

Additional File 1 of Tumor-derived KLK8 Predicts Inferior Survival and Promotes an Immune-Suppressive Tumor Microenvironment in Lung Squamous Cell Carcinoma

Identification of Molecular Markers Associated with the Progression and Prognosis of Endometrial Cancer: a Bioinformatic Study

LPCAT1 Acts As an Independent Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma

Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer: A field synopsis of observational study

Integrative Analysis of Differently Expressed Genes Reveals a 17-Gene Prognosis Signature for Endometrial Carcinoma.

LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

Exploration of a Novel Prognostic Risk Signatures and Immune Checkpoint Molecules in Endometrial Carcinoma Microenvironment

Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer

TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma